A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer.

被引：0
|
作者：
Sym, Sun Jin
Hong, Junshik
Jung, Minkyu
Park, Jinny
Cho, Eun Kyung
Lee, Jae Hoon
Lee, Won-Suk
Baek, Jeong-Heum
Shin, Dong Bok
机构：
[1] Gachon Univ, Gil Hosp, Dept Internal Med, Inchon, South Korea
[2] Gachon Univ, Gil Hosp, Inchon, South Korea
[3] Gachon Univ, Gil Hosp, Dept Gen Surg, Inchon, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14137
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer
    Sym, Sun Jin
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Lee, Won-Suk
    Baek, Jeong-Heum
    Park, Yeon Ho
    Shin, Dong Bok
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] A PHASE II TRIAL OF SALVAGE TREATMENT WITH GEMCITABINE AND S-1 COMBINATION IN HEAVILY PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sym, S. J.
    Hong, J.
    Jung, M.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Lee, W. -S.
    Baek, J. -H.
    Shin, D. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 151 - 152
  • [3] A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer
    Sym, Sun Jin
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Lee, Won-Suk
    Baek, Jeong-Heum
    Park, Yeon Ho
    Shin, Dong Bok
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A PHASE 2 TRIAL OF SALVAGE TREATMENT WITH GEMCITABINE AND S-1 COMBINATION IN HEAVILY PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sym, S. J.
    Hong, J.
    Ahn, H. K.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Lee, W.
    Baek, J.
    Park, Y. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S3 - S3
  • [5] Phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer.
    Yamaguchi, Kazuhisa
    Taniguchi, Hiroya
    Komori, Azusa
    Narita, Yukiya
    Uegaki, Shiori
    Nitta, Sohei
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] Combination of trastuzumab and gemcitabine as salvage therapy in heavily pretreated patients with metastatic breast cancer
    Bartsch, R.
    Wenzel, C.
    Pluschnig, U.
    Altorjai, G.
    Dubsky, P.
    Scheurer, R.
    Rottenfusser, A.
    Gnant, M.
    Zielinski, C. C.
    Steger, G. G.
    EJC SUPPLEMENTS, 2008, 6 (07): : 178 - 179
  • [7] A phase II trial of the combination gemcitabine plus vinorelbine in pretreated and heavily pretreated metastatic breast cancer patients, preliminary data.
    Cacciari, N
    Pinto, C
    Giaquinta, S
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 37 - 37
  • [8] Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: A multicenter phase II study
    Kakolyris, S.
    Kalbakis, K.
    Potamianou, A.
    Malamos, N.
    Vamvakas, L.
    Christophillakis, C.
    Tselepatiotis, E.
    Giassas, S.
    Mavrousis, D.
    Amarantidis, K.
    Georgoulias, V.
    ONCOLOGY, 2006, 70 (04) : 273 - 279
  • [9] Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: A multicenter phase II study
    Kakolyris
    ONCOLOGY, 2006, 71 (3-4) : 203 - 203
  • [10] A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer
    Huang, Mingzhu
    Yang, Yue
    Zhu, Xiaodong
    Chen, Zhiyu
    Zhang, Wen
    Wang, Chenchen
    Zhang, Xiaowei
    Qiu, Lixin
    Zhang, Zhe
    Zhao, Xiaoying
    Li, Wenhua
    Wang, Yusheng
    Guo, Weijian
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (06) : 513 - 521
12345